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Abstract
We have investigated the immunological and metabolomic impacts of Cry1Ab administration to mice, either as a purified
protein or as the Cry1Ab-expressing genetically modified (GM) MON810 maize. Humoral and cellular specific immune
responses induced in BALB/cJ mice after intra-gastric (i.g.) or intra-peritoneal (i.p.) administration of purified Cry1Ab were
analyzed and compared with those induced by proteins of various immunogenic and allergic potencies. Possible
unintended effects of the genetic modification on the pattern of expression of maize natural allergens were studied using
IgE-immunoblot and sera from maize-allergic patients. Mice were experimentally sensitized (i.g. or i.p. route) with protein
extracts from GM or non-GM maize, and then anti-maize proteins and anti-Cry1Ab–induced immune responses were
analyzed. In parallel, longitudinal metabolomic studies were performed on the urine of mice treated via the i.g. route. Weak
immune responses were observed after i.g. administration of the different proteins. Using the i.p. route, a clear Th2 response
was observed with the known allergenic proteins, whereas a mixed Th1/Th2 immune response was observed with
immunogenic protein not known to be allergenic and with Cry1Ab. This then reflects protein immunogenicity in the BALB/c
Th2-biased mouse strain rather than allergenicity. No difference in natural maize allergen profiles was evidenced between
MON810 and its non-GM comparator. Immune responses against maize proteins were quantitatively equivalent in mice
treated with MON810 vs the non-GM counterpart and no anti-Cry1Ab–specific immune response was detected in mice that
received MON810. Metabolomic studies showed a slight ‘‘cultivar’’ effect, which represented less than 1% of the initial
metabolic information. Our results confirm the immunogenicity of purified Cry1Ab without evidence of allergenic potential.
Immunological and metabolomic studies revealed slight differences in mouse metabolic profiles after i.g. administration of
MON810 vs its non-GM counterpart, but no significant unintended effect of the genetic modification on immune responses
was seen.
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Introduction
Food allergies, mainly IgE-mediated immediate reactions, are
increasing worldwide, particularly in Western countries. The most
common food allergens include peanut, soybean, tree nuts, wheat,
egg, milk, fish and sea foods, but many other foods may be involved
[1,2] and the prevalence of allergy to particular foods varies in
different geographic areas owing to dietary habits and environ-
mental conditions. The introduction on the market of novel foods,
particularly foods resulting from modern biotechnology, e.g.
genetically modified (GM) foods, has therefore raised the question
of the assessment of the potential allergenicity of the newly
expressed protein(s) and of the whole GM food. As no single test
or property definitely distinguishes allergens from non-allergens, the
allergenicity of a novel protein is currently assessed using a weight-
of-evidence approach [3] [4] [5] [6]. Although called into question
[7], the use of animal models has been encouraged by international
scientific committees to complement this approach.
Various animal models have been proposed for allergenicity
assessment (review in [8]). Mice have been widely used because
they share with humans many important immunological mecha-
nisms, such as Th1, Th2, Th17 and regulatory responses [9] [10].
Many immunological studies have been performed with BALB/c
mice, a Th2-biased high IgE responder strain mimicking atopic
individuals [11]. BALB/c mice have been used for the study of
both steps of the allergic reaction to various food allergens, i.e.
sensitization (the synthesis of specific IgE antibodies) and
elicitation (the appearance of symptoms upon challenge of
sensitized animals) [12,13] [14,15]. It has been proposed that
the intrinsic sensitizing potential of a novel protein can be assessed
by measuring the specific IgE antibody and Th2 cytokine
productions after administration without adjuvant. However,
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16346BALB/c, like other inbred congenic mice, are characterized by a
defined and restricted haplotype and false-negative IgE production
can be observed due to non-recognition of the administered
proteins by the class II major histocompatibility complex. The
capacity of a protein to induce the synthesis of IgG antibodies,
such as IgG1 or IgG2a antibodies which are Th2 or Th1 markers
respectively, should also be measured for a comprehensive
assessment [8]. Additionally, the comparison between the immune
response induced by administration of the novel protein and that
induced by a range of different proteins known to be weak or
strong sensitizers has been proposed to increase the sensitivity and
specificity of the test and the accuracy of the interpretation
[16,17].
Bacillus thuringiensis (Bt), a gram-positive bacterium producing
insecticidal inclusion bodies during sporulation, has been widely
used in insecticidal spray and some of its genes have been
introduced into many crops to make them resistant to insect
infestations. Among the different Bt proteins, Cry1Ab has been
introduced by genetic modification in various crops including so-
called insect-resistant maizes such as MON810. Because of the
specificity of the insect gut receptors, Bt proteins are considered
innocuous to mammals [18]. Cry1Ac, which has a structure very
close to that of Cry1Ab, has been shown to be immunogenic in
BALB/c mice, inducing a systemic and a mucosal immune
response with production of specific IgG, IgM and IgA antibodies
after i.p., i.g., intra-nasal or intra-rectal administration [19,20].
The N-terminal region of Cry1Ab, Cry1Ac and also of Cry1Aa,
another similar protein, may induce strong specific antibody
responses after intra-nasal or i.p. administration to BALB/c mice,
and Cry1Aa was shown to induce cytokine production in mouse
lymphocytes [21]. The induction of a specific immune response
was also observed in rats after ingestion of transgenic rice
containing or spiked with Cry1Ab protein [22] and 2 human T-
cell epitopes of Cry1Ab have been identified in vitro [23]. In
addition, a recent study suggested that feeding weaning and old
mice with MON810 maize may result in alterations of intestinal
and peripheral immune cell populations [24]. All these studies
demonstrate the intrinsic immunogenicity of Cry1A proteins,
although specific IgE were not assessed in animals experimentally
treated and never detected in sera from humans with various
allergies who might have been exposed to insect-resistant crops
[25–27].
We assessed the intrinsic immunogenic/allergenic potential of
Cry1Ab in BALB/c mice after administration of the purified
protein by different routes without adjuvant. We compared the
specific antibody responses and cytokine secretions thus induced
with those induced after administration of other proteins known to
display different immunogenic/allergic potencies [14,16], i.e.
keyhole limpet hemocyanin (KLH), considered as an immunogen
but not known to be an allergen, cow’s milk bovine b-lactoglobulin
(BLG), which is a moderate allergen, and peanut Ara h 1, which is
known as a most potent allergen. Cry1Ab is present at very low
levels in maize seeds and so we also analyzed the immune response
induced in mice after administration of protein extracts from
maize MON810 and its non-GM counterpart. Both maize protein
extracts were first characterized for their allergen contents and
profiles and Cry1Ab contents and then administered to mice via
the i.p. or i.g. route. Additionally, longitudinal metabolomic
studies were also performed in the mice treated (i.g. route) with
GM vs non-GM maize. Metabolomics complements the immu-
nological studies. As a non-targeted study, we used it to detect any
unintended effects of the genetic modification on the metabolism
of mice given MON810 vs non-GM maize protein extract. Such
metabolic changes may be explained by minor perturbations or
deregulations in the metabolic network in response to exposure to
these protein extracts via the i.g. route.
Methods
1. Apparatus, reagents, mice and ethics statement
Enzyme immunometric assays were performed in 96-well
microtiter plates (Immunoplate Maxisorb, Nunc, Roskilde, Den-
mark) using specialized Titertek microtitration equipment from
Labsystems (Helsinki, Finland). Unless otherwise stated, all
reagents were of analytical grade from Sigma (St Louis, MO).
Female BALB/cJ mice (Centre d’Elevage Rene ´ Janvier, France)
were housed under normal husbandry conditions and were
acclimated for two to three weeks before experimentation. All
experiments were performed according to the European Com-
munity rules of animal care and with permission 91–122 of the
French Veterinary Services. All experiments were covered by
agreement No. 2009-DDSV-074 (October 29th, 2009) from the
Veterinary Inspection Department of Essonne (France).
2. Production and characterization of anti-Cry1Ab
monoclonal antibodies
Anti-Cry1Ab monoclonal antibodies (mAbs) were produced by
conventional techniques according to De StGroth and Scheideg-
ger [28] and Grassi et al. [29] using Cry1Ab full-length protein
purified from Bacillus thuringiensis (i.e. protoxin, see section 2.3.1).
Twenty-five mAbs were obtained 20 of which were of IgG1
isotype and 4 of IgG2a isotype. Five complementarity groups, i.e.
recognizing different regions of Cry1Ab protein, were character-
ized, one of which was specific to the C-terminal part of the
protoxin [30]. Two complementary mAbs (i.e. mAb#120 and
mAb#95) were selected based on their epitopic specificity and
affinity, for ELISA determination of Cry1Ab. In addition, mAbs
from different complementarity groups were used as standards for
the quantification of anti-Cry1Ab IgG1 and IgG2a antibodies
produced in mice after i.p. or i.g. administration (see below).
3. Evaluation of the intrinsic immunogenicity of purified
Cry1Ab
3.1 Purified proteins. Extraction and purification of bovine
b-lactoglobulin (BLG) from cow’s milk were performed as
previously described [31]. Ara h 1 was extracted and purified
from roasted peanuts according to [32]. Cry1Ab protoxin was
produced from the B. thuringiensis 407- strain harboring the
pHT315Vcry1Ab plasmid [30,33]. Identity, purity and molecular
weight (MW) of all proteins were confirmed by HPLC using Akta
purifier and SDS-PAGE electrophoresis systems from Pharmacia
Biotech, completed by in-gel trypsin hydrolysis and analysis of
generated fragments by MALDI-TOF mass spectrometry (data
not shown; [30]). KLH was from Calbiochem (La Jolla, CA).
Protein concentrations were assessed using BCA assay from Pierce.
No endotoxin was detected in protein preparations, as determined
by the Limulus Amebocyte Lysate test from Sigma.
3.2 Analysis of the immune response induced after
administration of purified proteins. Seven-week-old female
BALB/cJ mice were given either 1 or 100 mg of each protein (i.e.
KLH, BLG, Ara h 1 or Cry1Ab) by the i.p. or i.g. route at days 1
and 15 without any adjuvant (n=5 per group, 200 mL/mouse).
Control mice received phosphate buffer saline (PBS, Gibco) (n=5
per group). Serum samples were obtained by puncturing the retro-
orbital venous plexus of mice at day 31 and specific antibodies
were measured by enzyme immunoassay (EIA) on antigen-coated
plates (5 mg/mL, diluted in 50 mM phosphate buffer pH 7.4,
100 mL/well). Serial dilutions (from 1/50 to 1/10
6) of individual
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phosphate buffer, 0.1% bovine serum albumin, 0.15 M NaCl,
0.01% sodium azide) and applied to coated plates for 18 h at
+4uC. After washing (0.01 M phosphate buffer pH 7.4, 0.05%
Tween 20), acetylcholinesterase (AChE)-labelled anti-IgE, IgG1 or
IgG2a antibodies were applied for 3 h at room temperature as
previously described [34]. Solid-phase bound AChE activity was
determined by addition of 200 mL/well of Ellman’s medium and
absorbance measurement at 414 nm [35]. Specific IgG1 and
IgG2a antibodies produced in mice receiving BLG were quantified
as previously described [34]. Quantitative enzyme immunoassays
for anti-Cry1Ab IgG1 and IgG2a were developed using
combinations of well-characterized anti-Cry1Ab mAbs of known
isotype as standard (i.e. mAbs #15, #68, #73, and #85 for IgG1
determinations and mAbs #39 and #95 for IgG2a
determinations) [30,34]. As no mAbs specific for KLH and Ara
h 1 were available, semi-quantifications were performed using the
same standard curves as those obtained in the same conditions for
anti-BLG specific antibody determination. Concentrations of
specific IgE antibodies were not quantified but results were
expressed as absorbance units at 414 nm (mAU414nm), whatever
the protein considered. Nonspecific binding (NSB) was determined
using EIA buffer instead of serum. Limit of detection was
determined as mean of NSB +3sn21. Mice given the different
proteins were compared with mice receiving PBS, using the
nonparametric Mann-Whitney test.
On day 35, all mice were sacrificed by vertebral dislocation and
spleens were harvested and pooled within each treatment group.
After lysis of red blood cells (180 mM NH4Cl, 17 mM Na2EDTA)
and several washes, splenocytes were resuspended in RPMI-10
(RPMI supplemented with 10% fetal calf serum, 2 mM L-
glutamine, 100 U penicillin, 100 mg/mL streptomycin – all from
Gibco). Cells were incubated in 96-well culture plates (10
6 cells/
well) in the presence of the same protein as that administered to
the mice (from 0.5 to 50 mg of protein/mL), RPMI-10 (negative
control), or concanavalin A (1 mg/mL, positive control) for 60 h at
37uC and 5% CO2. Supernatants were then removed and stored
at 280uC until further assay. IL-5 was assayed as described in
[36]. IL-4 and IFNc were assayed using commercial ELISA kits
following the manufacturer’s recommendations (CytoSet, Bio-
source International).
4. Analysis of the anti-maize proteins and anti-Cry 1Ab
immune responses and of the metabolomic profiles after
administration of MON810 maize protein extracts
4.1 Preparation and characterization of whole protein
extracts from MON810 and non-GM maize. Flours from
grains of MON 810 maize expressing Cry1Ab (DKC6575 cultivar)
and its conventional counterpart (Tietar) were used [37]. Both
cultivars were grown under same conditions. Ten grams of flour
were added to 20 mL of potassium phosphate buffer (50 mM,
pH 7.4), and homogenized using an Ultra-Turrax grinder (Janke
& Kunkel, IKA Labortechnik, Germany). After rotational shaking
for 18 h at 4uC, samples were centrifuged (1000 g, 20 min, +4uC)
and supernatants collected. Protein contents were assayed using
the BCA kit from Pierce. Protein contents in the extracts were
13.7 mg/mL and 13.9 mg/mL for the samples from the GM and
non-GM maize, respectively.
Qualitative and quantitative analysis of intrinsic allergens in
GM and non-GM maize protein extracts was then performed
using sera from self-reported maize-allergic patients 19392-CS and
20770-MH obtained from Plasmalab (WA, USA), which con-
tained respectively 20-30 kIU/l and 20 kIU/l of corn-specific IgE
as assayed using the Phadia CAP system (Pharmacia Diagnostics,
Uppsala, Sweden). Electrophoresis and western blot analysis was
then performed as following: 50 mL of protein extract from MON
810 or non-GM maize was mixed with 25 mL of 4X Laemmli
loading buffer (1.5 M Tris pH 6.8, 10% SDS, 1% b-mercapto-
ethanol, 40% glycerol, 1.25% bromophenol blue) and 25 mLo f
deionized water and heated at 90uC for 10 min. Electrophoresis
was performed by loading 12 mL of sample or SeeBlueH Plus2 Pre-
stained Standard (Invitrogen) on 12% SDS-PAGE gels. Migration
in Tris glycine buffer was performed at 10 mA for 120 minutes
and then at 20 mA for 60 minutes, using the Mini-Protean IIH cell
system from BioRad (CA, USA). Proteins from one gel were
stained using GelCodeH Blue Reagent (Thermo Scientific, Rock-
ford IL, USA). Proteins from other gels were transferred onto a
PVDF membrane using the Mini Trans-BlotH cell from BioRad
(36 V for 90 minutes) and then saturated according to the
manufacturer’s recommendations. The membrane was then cut
into strips which were incubated for 18 h at 4uC with 1/20 diluted
sera from the 2 maize-allergic patients. After washing, anti-human
IgE secondary antibodies were added (goat anti-human IgE-HRP,
1/2000; STAR96P; Serotech, UK). After 1-h incubation,
membranes were extensively washed and then stained with
Amersham ECL plus western blotting detection reagent, following
the manufacturer’s recommendations. Signals were visualized by
exposing a detection Kodak film to the blots and further developed
with X-ray developer reagents from Kodak.
In parallel, IgE specific to GM and non-GM maize proteins
were determined using enzyme allergosorbent tests (EAST) as
previously described [38]. Briefly, microtiter plates were coated by
passive adsorption with 5 mg/mL of GM or non-GM protein
extract (50 mM phosphate buffer, pH 7.4 for 24 h at 4uC). After
saturation for at least 4 h at room temperature with EIA buffer,
50 mL per well of serial dilutions of individual serum (1/5 to 1/
125, in EIA buffer) was dispensed. A standard curve was
determined using plates coated with an anti-human IgE (clone
LE27) and standard human IgE (World Health Organization) at
concentrations ranging from 10 to 0.08 IU/mL. After 24-h
incubation at 4uC and a wash step, a second anti-human IgE
antibody (clone BS17) labelled with AChE was used as a tracer.
After extensive washings, Ellman’s reagent was used as enzyme
substrate and the absorbance was measured at 414 nm.
Cry1Ab concentrations were determined on serial dilutions of
the protein extracts from non-GM and GM maize (from 1/100 to
1/7290) using an in-house ELISA developed within the EU-
funded CoExtra Project (GM and non-GM supply chain: their co-
existence and traceability) and validated using standard samples of
maize grain flours containing known concentrations of MON810
maize (i.e. 0, 0.5, 1 and 2.5%, kindly provided by the Institute for
Reference Materials and Measurements, EU-Joint Research
Centre, Geel). Standard flour samples (250 mg) were mixed with
2 mL of extraction buffer (0.1 M sodium carbonate pH 10, 0.5 M
NaCl, 0.05% Tween, 0.05% DTT and a protease inhibitor
cocktail [30]). Samples were agitated for 1 h at 20uC and then
centrifuged (3800 g, 15 min, +4uC). Supernatants were collected
and Cry1Ab was assayed using a sandwich ELISA. Capture
antibody (i.e. mAb #120, section 2.2) was passively immobilized
on 96-well microtiter plates for 18 h at 20uC( 5mg/mL in 50 mM
phosphate buffer pH 7.4, 100 mL/well). After washing and
saturation, serial dilutions of standard Cry1Ab or protein extracts
from non-GM and GM maize flours in EIA buffer were incubated
(100 mL/well) for 2 hours at 20uC. After washing, 100 mL of anti-
Cry1Ab mAb #95 (section 2.2) labelled with AChE were added to
plates and incubated for 2 h at 20uC. Plates were then extensively
washed and solid phase–bound AChE activity was determined by
addition of 200 mL/well of Ellman’s reagent [35].
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with GM and non-GM maize protein extracts. Three-week-
old female BALB/cJ mice were fed a maize protein–free diet
(Purified Diet 210, SAFE, Augy – France). Two weeks later, the
mice were sensitized to protein extracts from MON810 or the
non-GM counterpart. The procedures used were either i.p.
administration of 100 mg of protein/mouse emulsified with
incomplete Freund’s adjuvant on days 1 and 15 (n=8/group)
[13] or i.g. administration of 1 mg of protein mixed with 10 mgo f
cholera toxin/mouse on days 1, 7, 13, 19 and 26 (n=10/group)
[12]. Ten mice received PBS via the i.g. route (PBS mice). Serum
samples were obtained by puncturing the retro-orbital venous
plexus of mice at day 30 and antibodies specific to maize proteins
and to Cry1Ab were measured by immunoassays on antigen-
coated plates, as previously described. All sera were analyzed
individually at convenient dilution. After bleeding, all mice were
sacrificed by vertebral dislocation and spleens were harvested and
pooled within each treatment group. Cellular suspensions were
prepared as previously described. Cells were incubated in 96-well
culture plates in the presence of RPMI-10 or irrelevant antigen
(negative control), concanavalin A (1 mg/mL, positive control),
purified Cry1Ab (1, 5 or 20 mg/mL), or GM and non-GM maize
protein extracts (5, 25 or 125 mg of protein/mL) for 60 h at 37uC
and 5% CO2. Supernatants were then removed and stored at
280uC until further assay. IL-2, IL-4, IL-5, IL-10, IL-13, GM-
CSF, IFNc, TNFa and IL-17 were assayed using BioPlex
technology and the mouse cytokines kit from BioRad, following
the manufacturer’s recommendations.
4.3. Metabolomic analysis of mouse urine after i.g.
administration of MON810 vs non-GM maize protein
extracts. Metabolomics, as a holistic method used to
characterize the functioning of living systems, is useful here for
tentative detection of specific low-intensity metabolic effects that
could be related to exposure to protein extracts from either
MON810 or non-GM maize. Basically, this method uses a
stringent multivariate statistical procedure to mine metabolic
fingerprints obtained from a biological matrix to both discriminate
groups of individuals and display significant biomarkers. Here,
linear discriminant analysis (LDA) and orthogonal corrected PLS-
based discriminant analysis (OPLSDA) [39–40] were used to
discriminate the two groups of mice submitted to a time-course
study of the effects of maize protein extracts. In OPLSDA, a
regression model is calculated between the multivariate data and a
response variable that only contains group information.
Urine samples from individual identified mice given MON 810
or non-GM maize protein extracts by the i.g. route (see above)
were then collected before the first administration, and then on
days 27 and 28, i.e. 24 and 48 h after the last administration.
Urine samples were prepared by mixing urine (80–100 mL) with
phosphate buffer (600–620 mL, pH 7.4, 0.2 M) containing 10%
D2O as a field frequency lock and 0.05% sodium 3-trimethylsi-
lylpropionate-2,2,3,3-d4 (TMSP, internal standard) as a chemical
shift reference. Buffered urine samples were then centrifuged at
13000 g for 10 min to remove any precipitates, and aliquots of the
supernatants (600 mL) were transferred to 5 mm NMR tubes for
1H NMR analysis.
All
1H NMR spectra were recorded at 300 K on a Bruker
DRX-600 Avance NMR spectrometer (Rheinstetten, Germany)
operating at 600.13 MHz for
1H resonance frequency, using an
inverse detection 5 mm
1H-
13C-
15N cryoprobe attached to a
cryoplatform (the preamplifier cooling unit). The 1D ‘‘Improved
Watergate’’ sequence was used for suppression of water resonance.
Typically 128 free induction decays (FIDs) were collected into 32k
data points using a spectral width of 12 ppm. The FIDs were
multiplied by an exponential weighting function corresponding to
a line broadening of 0.3 Hz prior to Fourier transformation. The
acquired NMR spectra were phased, baseline-corrected and
referenced to TMSP resonance (d 0 ppm).
For assignment purposes, 2D correlation spectroscopy (COSY)
NMR spectra were also acquired for a urine sample. Sixty-four
transients per increment and 256 increments were collected into
2048 data points. The spectral width in both dimensions was
10 ppm. Before Fourier transformation, an unshifted sine-bell
apodization function was applied to the free induction decays from
the COSY spectra.
The NMR spectra over the range of d 0.5–10.0 ppm were
reduced by using AMIX (Bruker Analytik, Rheinstetten, Ger-
many) to regions, each 0.01 ppm wide, and the signal intensity in
each region was integrated. The region d 4.5–6.5 ppm was
removed to eliminate baseline effects of imperfect water resonance
suppression. Normalization to the total sum of the spectrum was
carried out on the data before multivariate statistical analysis.
From the 950 initial metabolic variables extracted from spectra,
the multidimensional scaling procedure was repeatedly applied to
select 395 fully informative metabolic variables, to which were
applied an orthogonal signal correction procedure based on a
partial least squares (PLS) regression using dummy variables
designed according to the ‘‘time’’ and ‘‘cultivar’’ effects. Nearly
84% of the initial metabolic information was kept after discarding
on a single orthogonal component the non-modeled information
from the initial dataset. One-way ANOVA considering the
different groups of animals, which correspond to the combination
of ‘‘cultivar’’ and ‘‘time’’ factors, was further applied at a 0.01
alpha risk and 315 variables thus selected were then submitted the
Carlier algorithm [41] to select 64 uncorrelated variables, of which
only the 25 most informative were used to perform multivariate
analyses such as LDA and orthogonal corrected PLS-based
discriminant analysis O2-PLS-DA using Splus 2000 (v2.0,
Insightful Corp., Seattle, WA) including Mass and Multidim
(www.lsp.ups-tlse.fr/Carlier/Logiciel.html) libraries, SAS (v8.01,
SAS Institute Inc., Cary, NC) and Simca P (v 12.0, Umetrics,
Umea, Sweden) software.
Results
1 Analysis of the immune response induced by
administration of purified proteins
The intrinsic immunogenic/allergenic potential of Cry1Ab was
assessed in BALB/cJ mice by administering the purified protein by
different routes without adjuvant. The humoral response (i.e.
specific antibody production) and the cellular response (cytokine
production by reactivated splenocytes) were analyzed and
compared with the responses induced after administration of
KLH, BLG and Ara h 1.
1.1. Analysis of the immune response induced after i.g.
administration. No specific IgE antibody production was
observed after i.g. administration of either 1 or 100 mg of any of
the different proteins. Low levels of specific IgG1 and/or IgG2a
(,20 ng/mL) were detected in a few mice receiving 1 mgo f
proteins. Antibody responses were less frequent at the 100 mg than
at the 1 mg dose (data not shown). At both doses, high specific
secretion of IFNc was observed in the KLH group, but no antigen-
specific secretion of Th1 or Th2 cytokines by reactivated spleen
cells was detected in other groups, whatever the dose (data not
shown).
1.2. Analysis of the immune response induced after i.p.
administration. I.p. administration of 1 mg of KLH induced
the production of anti-KLH-specific IgG1 and IgG2a antibodies,
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compared with control mice (Figure 1). After administration of
100 mg of KLH the concentrations of anti-KLH-specific IgG1 and
IgG2a antibodies were approximately 10-fold higher, whereas the
IgE specific response was no longer statistically significant since
only one mouse out of five reacted. No significant specific antibody
responses were induced after BLG administration, whatever the
dose. Conversely, i.p. administration of Ara h 1 induced intense
production of specific IgG1 and IgE antibodies at both doses.
IgG2a antibodies were also produced at concentrations
comparable to those induced after KLH administration. The
specific antibody response to Cry1Ab was characterized by an
intense production of anti-Cry1Ab IgG1 and IgG2a antibodies.
The specific IgG1 response induced by administration of the
100 mg dosage was 20-fold higher than that induced by the 1 mg
dose, while the IgG2a responses were equivalent. A low and
variable but statistically significant IgE response was observed only
in mice which received the 1 mg dose of Cry1Ab.
After antigenic reactivation, splenocytes from mice given KLH
by the i.p. route showed no or low secretion of IL-5, but intense
secretion of IFNc, whereas those from mice treated with Ara h 1
showed marked secretion of IL-5 and weak secretion of IFNc,
whatever the dose administered (Figure 2). In mice treated with
BLG, IFNc and IL-5 secretions were observed, indicating a weak
specific Th1/Th2 response at the 1 mg dosage with an increased
polarization toward a Th2 response at the 100 mg dose, although
no specific antibody production was detected in the sera of these
mice. Spleen cells from mice given 1 mg Cry1Ab showed strong
IL-5 and IFNc secretions, but both IL5 and IFNc secretions were
decreased after administration of the 100 mg dose, IL5 secretion
then being similar to that induced by the 1 mg dose of KLH.
2. Effects of administration of MON810 maize to mice
2.1 Characterization of whole-protein extracts. Before
administration to mice, both maize protein extracts were
characterized in terms of their Cry1Ab contents and intrinsic
allergen contents and profiles. The standard curve obtained with
purified Cry1Ab in the sandwich immunoassay we have developed
is shown in Figure 3A. The calculated limit of quantification (mean
NSB+10sn21) is 10 pg/mL of Cry1Ab, and convenient precision
of this ELISA was also obtained, as assessed by determining the
intra- and inter-assay coefficients of variation (CV,10%, not
shown). Dilution curves obtained with the reference materials
containing known concentrations of either MON810 or standard
purified Cry1Ab are shown in Figure 3B. No signal was detected
with the non-GM reference material (not shown). Curves obtained
are parallel, which demonstrates the efficiency and specificity of
the assay. Cry1Ab concentrations measured were 26.96, 48.7, and
Figure 1. Specific IgG1, IgG2a and IgE antibodies induced after i.p. administration of purified KLH, BLG, Ara h1 or Cry1Ab. Specific
IgG1 (N, left axis), IgG2a (o, left axis) and IgE (*, right axis) antibodies were assayed in sera of individual BALB/cJ mice after two i.p. administrations of 1
(A) or 100 mg( B) of each protein, without adjuvant. Bars represent the mean of 5 mice per group. Nonspecific binding (NSB) was determined using
EIA buffer instead of serum. Limit of detection was determined as the mean of NSB +3sn21.ap ,0.05 when comparing mice receiving protein with
mice receiving PBS (not shown), nonparametric test.
doi:10.1371/journal.pone.0016346.g001
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MON810 maize at concentration levels of 0.5, 1 and 2.5%,
respectively, demonstrating the accuracy of the assay. Using this
assay, extracts administered to mice were characterized for their
Cry1Ab contents. No Cry1Ab was detected in the extract from the
non-GM maize (Tietar). MON 810 extract (DKC6575 cultivar)
contained 0.18 mg/mL Cry1Ab, corresponding to 0.0013% of the
protein content.
The allergen repertoires of the GM and non-GM maize were
then compared by electrophoresis (Figure 4A) and immunoblot-
ting using 2 sera from maize-allergic patients (Figure 4B–C). The 2
sera displayed different patterns of recognition by IgE antibodies,
but for each serum no differences were observed between GM and
non-GM maize. Moreover, concentrations of human specific IgE
assayed on plates coated with GM or non-GM maize protein
extract were comparable (Figure 4D). These results thus indicate
that the genetic modification did not result in unintended
qualitative and/or quantitative modification of expression of
intrinsic allergens.
2.2. Specific anti-maize and anti-Cry1Ab immune
response after administration of MON810 maize.
Characterized maize protein extracts were then administered to
mice either with cholera toxin (i.g. route) or IFA (i.p. route), two
protocols that efficiently sensitize BALB/c mice to whole foods
[12,13]. The immune responses induced by GM vs non-GM maize
were then compared within each protocol of sensitization. In each
case, there was significant production of IgE (Figure 5A) and IgG1
(Figure 5B) antibodies specific to maize proteins, compared with
PBS mice (p,0.05, Kruskal-Wallis test and Dunn’s multiple
comparison test). This demonstrated that the mice were efficiently
sensitized to maize proteins in our experimental conditions. For
each route of administration, no differences in IgE and IgG1
antibody responses to maize proteins were observed between mice
treated with the GM or non-GM maize. No difference in
determination was observed whatever the ELISA procedure
used, i.e. whatever the extract immobilized on the microtiter
plate (Figure 5). In the same way, no significant difference in Th1,
Th2 or Th17 related–cytokine secretion was seen after GM and
non-GM maize protein extract restimulation of splenocytes from
the treated animals, whatever the route and extract used for
immunization (data not shown). No specific anti-Cry1Ab antibody
was detected in serum from mice given the GM maize extract,
after either i.g. or i.p. sensitization, and no cytokine production
was detected after Cry1Ab reactivation of splenocytes from the
corresponding mice.
2.3 Metabolomic analysis of urine from mice given maize
protein extracts by the i.g. route. As a complement to the
targeted analysis of the immune response, we used a non-targeted
approach using metabolomics to detect any unintended and
unexpected effects provoked by i.g. exposure to GM maize protein
extracts.
1H NMR fingerprinting of urine collected from individual
mice before i.g. administration and either 24 or 48 h after the last
administration (i.e. on Days 27 and 28) gave a time-dependent
progression of metabolic signatures which accounted for 86% of the
between-group variance (1
st discriminant axis) and a difference
between control and maize protein administration (6.3% of the
between-group variance, 2
nd discriminant axis), with no difference
resulting from the administration of the GM vs the non-GM (not
shown). When this first data set was restricted to the study of the final
experimental situation after the 5
th i.g. administration on Day 26, it
was possible to detect more subtle but significant metabolic variations.
With such a data set, for which a prior orthogonal signal correction
based on ‘‘time’’ and ‘‘cultivar’’ factors is made, keeping 49.4% of the
initial information, it is possible again to detect a significant change in
the metabolic signature between the 27
th and 28
th days, which
represents 84.2% of the between-group variance and is explained by
the 1
st linear discriminant axis (LD1, p,0.0001) (Figure 6A).
Interestingly, the LD2, which accounts for 9.4% of the between-
group variance, discriminates between control animals and maize
protein–treated ones (p,0.0001). As for LD1, the 3
rd LD (LD3) with
4% of the variance is well explained by the day-to-day variation of the
mouse metabolome (p,0.0001). This likely explains the clear
opposition on the factorial projection between the group of animals
treated with non-GM maize proteins, which were analyzed on the
27
th day, and the group of animals treated with MON 810 proteins,
w h i c hw e r ea n a l y z e do nt h e2 8
th day (Figure 6B). It is only on the 4
th
LD explaining 1.7% of the between-group variance that metabolomic
variation depending only on the cultivar factor is seen (p,0.0001,
Figure 6C). On the factorial plan 364, the trajectory from D27 to
D28 for mice treated with non-GM maize proteinsis parallel to that of
control animals, but orthogonal to the trajectory of mice treated with
MON 810 proteins. The same LD axes were found with an O2-PLS
discriminant analysis, which is appropriate to the data treatment of
such a low rank variance-covariance matrix (not shown).
Metabolic biomarkers were identified from this discriminant
analysis. Following the last administration on day 26, a relative
general decrease in urinary excretion of myo-inositol (r=20.97),
hippurate (r=20.87) and taurine (r=20.78) was seen, with a
parallel increase in creatine (r=0.98) (Table 1, axis 1). The second
discriminant axis explains the differentiation between maize-
Figure 2. Cytokines secreted by splenocytes from mice given KLH, BLG, Ara h1 or Cry1Ab by the i.p. route. Splenocytes from BALB/cJ
mice after i.p. administration of PBS (white bars), 1 mg (gray bars) or 100 mg (black bars) of KLH, BLG, Ara h1 or Cry1Ab were reactivated ex vivo with
50 mg of the corresponding antigen. Expected results were obtained from positive (ConA) and negative controls (medium alone) (data not shown).
doi:10.1371/journal.pone.0016346.g002
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excretion of threonine (r=20.96) and phosphocholine
(r=20.85) and a relative decrease in taurine excretion in maize
protein–treated mice (r=0.91). The biomarker-based interpreta-
tion of the last two LD is more complex. The difference between
the mice treated with the non-GM maize proteins and those
treated with the MON 810 proteins is well explained considering
the LD3 by a lower excretion of both phenylalanine (r=20.83)
and hippurate (r=20.53) and a higher excretion of tryptophan
(r=0.53) in the latter mice. In parallel, the difference between
MON 810–treated mice analyzed on day 27 and the same mice
analyzed on day 28 is well explained by a relative increase in
excretion of some dicarboxylic acids (r=20.88), taurine
(r=20.48) and triethylamine (r=20.37) in the latter group
(Table 1, axes 3 and 4). All these observations cannot be simply
and directly related to immune or inflammation biomarkers.
Discussion
To analyze the intrinsic immunogenicity and potential impact
of exposure to Cry1Ab protein on the immune response of mice,
we first performed i.g. or i.p. administration of the purified protein
Figure 3. Sandwich immunoassay of Cry1Ab. A. Standard curve obtained with purified Cry1Ab protoxin in sandwich immunoassay using
mAb#120 passively adsorbed on microplates as capture antibody and AChE-labeled mAb#95 as tracer. Mean +/2 SD is represented. Each point is
the result of duplicate measurements, except NSB (EIA buffer alone, n=8). The limit of detection, defined as the lowest concentration of standard
Cry1Ab inducing a signal statistically significantly higher than NSB (i.e. mean+3sn21) is shown in the insert as a black line. B. Extracts from reference
maize powders containing MON810 maize mass fraction level of 0.5% (N), 1% (.) or 2.5% (X) (2- to 250-fold dilutions) or standard Cry1Ab (10 ng/
mL, 2- to 128-fold dilutions, #) were assayed using this sandwich immunoassay. All dilution points were assayed in duplicate. Results are expressed
as mean of absorbance values (mAU at 414 nm) +/2 SD. No signal was detected for non-GM reference maize (not shown).
doi:10.1371/journal.pone.0016346.g003
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response and cytokine secretion profile of mice receiving Cry1Ab
with those induced by administration of KLH (a highly
immunogenic protein not known to be an allergen), BLG (a
moderate allergen) or Ara h1 (a strong allergen) [14]. We did not
detect significant amounts of specific antibodies after i.g.
administration of any of the proteins. Notably, no anti-Cry1Ab
IgG1 or IgG2a antibodies were detected after i.g. administration
of 100 mg Cry1Ab, whereas such responses were induced in mice
receiving the same doses of Cry1Ac by this route according to
[20]. This is surprising considering the 86% amino acid sequence
homology between Cry1Ab and Cry1Ac proteins and is likely due
to the presence of endotoxin contaminating the bacterial
preparation of recombinant Cry1Ac used in [20]. Conversely,
i.p. administration of the different proteins generally resulted in
the induction of an immune response. In the present study, 100 mg
and 1 mg of KLH or Cry1Ab induced only a Th1 or a mixed Th1/
Th2 response, respectively. The administration of BLG induced
only a weak cellular Th2 response at the dose of 100 mg, whereas
that of Ara h1 induced a strong Th2 response whatever the dose
administered. A clear Th2 response was then observed for the
strong allergen Ara h 1, whatever the dose, and to a lesser extent
for BLG. The anti-Cry 1Ab immune response could not be
distinguished from that induced by KLH, which is considered as a
nonallergenic protein. Administration of low doses of proteins has
previously been reported to favor the induction of IgE in BALB/c
mice independently of the intrinsic allergenicity of the protein [42–
43]. It appears that high levels of antigen result in selective
stimulation of Th1 cells, which produce IFNc, and diminished
activation of IL-4-producing Th2 cells [44]. The observed mixed
Th1/Th2 response at low doses of Cry1Ab and KLH should then
reflect the protein immunogenicity in a Th2-biased strain of mice
rather than allergenicity. Conversely, the clear Th2 response
observed after administration of high doses of Ara h 1 or BLG
reflects their intrinsic allergenicity. Our results in the BALB/c
mouse thus show that i.g. administration of purified Cry1Ab had
no impact on the immune response and confirmed previous
Figure 4. A–C: Electrophoretic pattern and IgE-binding analysis
of protein extracts from MON810 and non-GM maize: Protein
extracts from MON 810 and its conventional counterpart were
separated on 12% acrylamide gel and proteins were stained (A). After
transfer to PVDF membrane, IgE binding proteins (i.e. allergens) were
revealed by western blotting with the sera of 2 maize-allergic patients,
i.e. #20770-MH (B) and #19392-CS (C). Specific IgE concentrations (D)
in the same sera were determined on GM (open bar) and non-GM (black
bar) protein extract coated plates. Bars represent mean+/2SEM
obtained for 3 different dilutions of each serum, each assayed in
duplicate.
doi:10.1371/journal.pone.0016346.g004
Figure 5. Specific IgE and IgG1 antibodies induced after i.g. or
i.p. administration of GM vs non-GM maize extracts. Mice were
given protein extracts from MON 810 or non-GM comparator via the i.p.
route (100 mg of protein/mice emulsified with incomplete Freund’s
adjuvant) on days 1 and 15 (n=8/group) or via the i.g. route (1 mg of
protein mixed with 10 mg of cholera toxin) on days 1, 7, 13, 19 and 25
(n=10/group). Ten mice received PBS via the i.g. route (PBS mice).
Specific IgE (A) and IgG1 (B) antibodies were assayed on microtiter
plates coated with non-GM (open circles) or MON810 (black symbols)
maize protein extracts. For each group, data of individual serum
samples collected on day 30 and the corresponding median values are
expressed as absorbance values (mAU at 414 nm). Sample dilutions
were 1/40 for assays of IgE antibodies, and 1/4000 (i.g. treated groups)
or 1/200000 (i.p. treated groups) for assays of IgG1 antibodies.
doi:10.1371/journal.pone.0016346.g005
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days 27 and 28. The four LD are highly significant (p,0.0001) and the 3 respective factorial maps are displayed here: 162( A), 263( B)a n d3 64( C). The
cultivar names are displayed on the factorial maps with the .2 and .3 suffixes designating the urine collection performed on days 27 and 28, respectively.
doi:10.1371/journal.pone.0016346.g006
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without evidencing allergenicity.
Cry1Ab is expressed at very low levels in MON810 maize, i.e.
ca. 0.0013% of the protein content in the present study. Therefore
we also investigated the immune response to Cry1Ab administered
within MON810 grains. We first tried to detect any possible
unintended effect of the genetic modification on the allergenicity
of the whole crop that might result in alteration of the quantitative
and qualitative expression patterns of endogenous maize allergens
in MON810 vs its conventional counterpart. No differences in the
allergen repertoire were detected by IgE-immunoblot studies using
sera from 2 maize-allergic patients. This confirms the results of the
gene expression profiling studies performed on leaves of the same
GM and non-GM lines [37]. The immune response was then
analyzed in mice experimentally sensitized by i.p. or i.g.
administration of whole protein extracts from GM or non-GM
maize in the presence of appropriate adjuvants. All mice were
sensitized to maize proteins as demonstrated by the production of
specific IgE and IgG1 antibodies against maize proteins and Th2
cytokine secretions by reactivated spleen cells, but no differences in
anti-maize protein specific IgE and IgG1 titers were observed after
i.p. or i.g. administration of whole protein extracts from either the
GM or the non-GM maize. In addition, no anti-Cry1Ab humoral
and cellular immune responses were detected in mice that received
the protein extract from MON810 maize.
Metabolomics easily enables quantitative and dynamic study of
the perturbation of living systems during or after exposure to
compounds that may have biological impacts [45]. In the present
study, metabolomics was used as a non-targeted approach to
detect any unintended and unexpected effects of the GM maize
protein extract. It was considered complementary to the targeted
analysis of the immune response, to allow comprehensive
assessment of the impact of exposure to GM maize in mice,
although both approaches might not be directly related. Clearly,
no early biomarkers of immunological or inflammatory processes
were observed. Effects of the repeated intra-gastric administrations
of maize proteins accounted for less than 10% of the complete
metabolic variance analyzed in this experiment, the main factor
accounting for the change in the metabolic fingerprint being the
age of the animals. A parallel progression of the urinary metabolic
pattern of mice treated with the 2 maize protein extracts is shown
on the 2
nd and 3
rd discriminant axes. It is only with the 4
th axis
that a ‘‘cultivar’’ effect is detectable, which represented 1.7% of
the metabolic information. This figure was calculated using an
OSC-PLS–based data correction, and hence represents less than
1% of the initial metabolic information. This so-called ‘‘cultivar’’
effect includes both the influence of the natural genetic
background of the 2 maize lines (i.e. MON810 and the
conventional counterpart) and the possible impact of the genetic
modification itself. The latter effect, if any, would thus account for
less than 1% of the metabolic variance.
In conclusion, using the BALB/c mouse model in particular
experimental conditions of exposure, we have demonstrated that
Cry1Ab is immunogenic and may induce a mixed Th1/Th2
Table 1. Metabolic biomarkers identified from discriminant analysis.
Chemical shift
(ppm) Assignment Axis 1 Axis 2 Axis 3 Axis 4
r rank r rank r rank r rank
3.93 creatine 0.98 1 0.19 20.01 0.05
4.09 myo-inositol 20.97 2 20.20 0.08 20.09
3.87 glycogen (?) 20.91 3 0.14 20.22 0.28
7.55 hippurate 20.87 4 0.25 20.25 20.34
3.61 myo-inositol/glycogen 20.85 5 20.12 20.27 0.37
3.20 choline 20.80 6 0.18 20.48 7 20.31
3.40 taurine 20.78 7 0.58 11 0.05 20.20
4.25 threonine 0.004 20.96 1 20.01 20.25
3.29 taurine 20.34 0.91 2 0.11 20.20
4.18 phosphocholine 20.001 20.85 3 0.50 6 0.10
3.30 taurine 20.38 0.76 4 0.15 20.48 4
4.16 lactate 0.33 20.76 5 0.43 0.29
7.27 phenylalanine 0.06 20.21 20.83 1 0.48 5
3.68 ? 20.004 20.52 13 20.60 2 0.51 2
7.69 tryptophan 0.77 8 20.28 0.54 3 0.22
7.85 hippurate 20.59 9 20.52 12 20.53 4 0.29
4.17 lactate 20.44 20.72 6 0.53 5 0.04
0.85 dicarboxylic acids 20.22 0.38 20.15 20.88 1
1.89 arginine/lysine 20.35 0.69 7 0.22 20.50 3
2.06 N-acetylglycoproteins 20.34 20.68 9 0.32 0.38 6
2.88 trimethylamine 20.45 11 0.69 8 20.09 20.37 7
1.59 dicarboxylic acids 0.53 10 20.58 10 0.43 0.34 8
Assignment of significant variables explaining the 4 first components displayed by a linear discriminant analysis performed on OSC-PLS–corrected data corresponding
to the late urine collections performed on days 27 and 28.
doi:10.1371/journal.pone.0016346.t001
In Vivo Impacts of Cry1Ab or MON810 Administration
PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16346immune response when it is administered as a purified protein by
the i.p. route. The same response was observed when considering
KLH and no allergenic potency could then be evidenced for
Cry1Ab. This effect was not observed after administration of a
protein extract from MON810 which resulted in an immune
response against maize proteins but not against Cry 1Ab.
Metabolomic studies on urine from treated mice (i.g. route)
showed a low ‘‘cultivar’’ effect, which represented 1.7% of the
OSC-corrected metabolic information, and in which the genetic
modification would account for less than 1%. More GM and non-
GM cultivars should be included in targeted studies to achieve a
more detailed analysis and interpret a possible biological
significance of this effect.
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